

NT-proBNP modestly improves CVD risk prediction in women

24 October 2014



More information: [Full Text \(subscription or payment may be required\)](#)
[Editorial \(subscription or payment may be required\)](#)

Copyright © 2014 [HealthDay](#). All rights reserved.

(HealthDay)—N-terminal pro-B-type natriuretic peptide (NT-proBNP) modestly improves cardiovascular disease (CVD) risk prediction for women, according to a study published in the Oct. 28 issue of the *Journal of the American College of Cardiology*.

Brendan M. Everett, M.D., M.P.H., from the Brigham and Women's Hospital and Harvard Medical School in Boston, and colleagues examined the correlation between NT-proBNP and incident CVD in [women](#) in a prospective case-cohort. Data were included for 1,821 incidence cases of CVD within the Women's Health Initiative observational study and a randomly selected reference cohort of 1,992 women without CVD at baseline.

The researchers observed higher median levels of NT-proBNP at study entry among incident cases than among controls (120.3 versus 100.4 ng/L; P

"In this multiethnic cohort of women with numerous CV events, NT-proBNP modestly improved measures of CVD [risk prediction](#)," the authors write.

Several authors disclosed financial ties to the pharmaceutical industry.

APA citation: NT-proBNP modestly improves CVD risk prediction in women (2014, October 24) retrieved 22 June 2022 from <https://medicalxpress.com/news/2014-10-nt-probnp-modestly-cvd-women.html>

This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.